Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
On September 28, 2026, the U.S. Food and Drug Administration (FDA) approved tavapadon tablets for the treatment of Parkinson’s disease…
VJNeurology brings you an article on the evolving pharmacologic treatment landscape for movement disorders, including Parkinson’s disease, Huntington’s disease, essential…
On February 4, 2025, the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride infusion), formerly known as SPN-830,…
On October 17, 2024, AbbVie announced the U.S. Food and Drug Administration (FDA) approval of foslevodopa-foscarbidopa, marking the first and…
Synucleinopathies are a group of neurodegenerative disorders noted for the abnormal accumulation of misfolded α-synuclein (αSyn) which forms toxic inclusions…
Learn more about the major research themes in Parkinson’s disease, discussed at the International Congress of Parkinson’s Disease and Movement…
Discover updates from major clinical trials in myasthenia gravis, Parkinson’s disease & ALS presented at AAN 2021!
VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.
VJNeurology uses cookies, including analytics and marketing, to understand how the site is used and improve it. Optional cookies are on unless you turn them off.
Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.
You can change your choice at any time on our Cookie Policy page, linked at the bottom of every page.